Arsenic trioxide (ATO) has been shown to be the most effective single agent in acute promyelocytic leukaemia (APL) and has been approved for the treatment of relapsed patients both in the US and Europe. The role of ATO in front-line therapy of APL is under investigation.

Breccia, M., Cicconi, L., LO COCO, F. (2014). ATRA + ATO: Has a new standard of care been established in low-risk acute promyelocytic leukaemia?. CURRENT OPINION IN HEMATOLOGY, 21(2), 95-101 [10.1097/MOH.0000000000000023].

ATRA + ATO: Has a new standard of care been established in low-risk acute promyelocytic leukaemia?

LO COCO, FRANCESCO
2014-01-01

Abstract

Arsenic trioxide (ATO) has been shown to be the most effective single agent in acute promyelocytic leukaemia (APL) and has been approved for the treatment of relapsed patients both in the US and Europe. The role of ATO in front-line therapy of APL is under investigation.
2014
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Standard of Care; Treatment Outcome; Tretinoin
Breccia, M., Cicconi, L., LO COCO, F. (2014). ATRA + ATO: Has a new standard of care been established in low-risk acute promyelocytic leukaemia?. CURRENT OPINION IN HEMATOLOGY, 21(2), 95-101 [10.1097/MOH.0000000000000023].
Breccia, M; Cicconi, L; LO COCO, F
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/160485
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact